Skip to main content
Log in

Do we really need prognostic factors for breast cancer?

  • Plenary lecture, 15th Annual San Antonio Breast Cancer Symposium
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

The role of prognostic factors in optimizing treatment for breast cancer patients has clearly changed with the trend toward general use of adjuvant therapy. Nevertheless, there are at least three situations in which prognostic factors could be helpful. The first is to identify patients whose prognosis is so good that adjuvant therapy after local surgery would not be cost-beneficial. The second is to identify patients whose prognosis is so poor that a more aggressive adjuvant approach would be warranted. The third is to identify patients likely to be responsive or resistant to particular forms of therapy. Here we will discuss all of these situations, together with the appropriate cutpoint analyses and validation of individual prognostic factors and their combination into prognostic indexes which may make the discrimination of patient subsets more reliable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1–15,71-85, 1992.

    Google Scholar 

  2. Anonymous: NIH Consensus Conference. Treatment of early-stage breast cancer. J Am Med Assoc 265: 391-395, 1991.

  3. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187, 1989.

    Google Scholar 

  4. Rosen PP, Groshen S, Kinne DW: Prognosis in T2M0N0 stage I breast carcinoma: a 20-year follow-up study. J Clin Oncol 9:1650–1661, 1991.

    Google Scholar 

  5. Tabar L, Fagerberg G, Day NE, et al: Breast cancer treatment and natural history: new insights from results of screening. Lancet 339:412–414, 1992.

    Google Scholar 

  6. McGuire WL, Clark GM: Prognostic factors and treatment decisions in node-negative breast cancer. N Engl J Med 326:1756–1761, 1992.

    Google Scholar 

  7. Haybittle JL, Blamey RW, Elston CW, et al: A prognostic index in primary breast cancer. Br J Cancer 45: 361–366, 1982.

    Google Scholar 

  8. Galea MH, Blamey RW, Elston CW, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22:207–219, 1992.

    Google Scholar 

  9. Hilsenbeck SG, Clark GM, McGuire WL: Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat 22:197–206, 1992.

    Google Scholar 

  10. Ciocca DR, Tandon AK, Fuqua SAW, et al: Heat shock protein hsp70 with axillary lymph node-negative breast cancer patients: prognostic implications. J Natl Cancer Inst 85:570–574, 1993.

    Google Scholar 

  11. Ravdin PM: Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat 24: 219–226, 1993.

    Google Scholar 

  12. Osborne CK: Prognostic factors for breast cancer: have they met their promise? J Clin Oncol 10:679–682, 1992.

    Google Scholar 

  13. Clark GM, Wenger CR, Beardslee S, et al: How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer 71:2157–2162, 1993.

    Google Scholar 

  14. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182, 1987.

    Google Scholar 

  15. Clark GM, McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51:944–948, 1991.

    Google Scholar 

  16. Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in node-negative breast cancer. Prognostic significance of overexpression influenced by presence of in situ carcinoma. J Clin Oncol 10:599–605, 1992.

    Google Scholar 

  17. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049–1056, 1992.

    Google Scholar 

  18. Muss H, Thor A, Kute T, et al: erbB-2 (c-cerbB-2; HER-2/neu) and S-phase fraction predict response to adjuvant chemotherapy in patients with node-positive breast cancer: Cancer and Acute Leukemia Group B Trial 8869. Proc ASCO 12:72, 1993.

    Google Scholar 

  19. Ciocca DR, Fuqua SAW, Lock-Lim S, et al: Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 52:3648–3654, 1992.

    Google Scholar 

  20. Oesterreich S, Weng C-N, Qiu M, et al: The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res, in press.

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clark, G.M. Do we really need prognostic factors for breast cancer?. Breast Cancer Res Tr 30, 117–126 (1994). https://doi.org/10.1007/BF00666054

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00666054

Key words

Navigation